Core Viewpoint - The report outlines the ongoing supervision and assessment of Suzhou Saifen Technology Co., Ltd. by CITIC Securities, focusing on the company's financial performance, core competencies, and potential risks associated with its operations in the chromatography industry. Summary by Sections Continuous Supervision Overview - CITIC Securities conducted a site inspection of the company from August 13 to August 14, 2025, reviewing governance documents, financial management, internal controls, and fundraising management [1]. Issues and Rectification - No significant issues were identified during the supervision period [2]. Major Risk Items - **Core Competitiveness Risk**: The company has developed unique technologies over 20 years, including microsphere synthesis and surface modification. Failure to protect these technologies could weaken its market position [2]. - **Operational Risks**: The company faces challenges in managing its overseas subsidiary, which accounts for 18.20% of its revenue, including risks related to local compliance and currency fluctuations [4]. Financial Performance - The company reported a revenue of 182.63 million yuan in the first half of 2025, a 19.76% increase year-on-year. Net profit attributable to shareholders was 53.66 million yuan, up 40.91% [17]. - The cash flow from operating activities was 35.72 million yuan, reflecting a 36.32% increase due to higher sales [17]. Core Competitiveness - The company possesses advanced microsphere synthesis technology, surface modification techniques, and functional modification capabilities, which are critical for producing high-quality chromatography media [18][19]. - The company has established a comprehensive product range, including over 100 types of chromatography media and more than 1,000 specifications of analytical columns, catering to various applications in biopharmaceuticals [20][21]. Industry Risks - The company faces risks from policy changes in the pharmaceutical industry, which could slow down growth and affect demand for its chromatography products [9][10]. - Increased competition from both domestic and international players in the chromatography market poses a threat to the company's market share [14][13]. Quality Management - The company has obtained ISO 9001:2015 certification and adheres to GMP guidelines for quality management, ensuring high product quality and consistency [23]. Research and Development - The company invested 2.39 million yuan in R&D in the first half of 2025, representing 13.09% of its revenue, with a focus on enhancing its product offerings and technological capabilities [24].

Investment Rating - The report maintains a "Buy" rating for the company [4][8]. Core Insights - The company has shown stable revenue growth with a significant increase in net profit, driven by effective cost control and increased government subsidies [10]. - The analysis segment has stable growth, while the industrial purification segment has experienced rapid growth, particularly in the GLP-1 drug purification market [10]. - The trend of domestic substitution is becoming established, and the company is making orderly progress in overseas market expansion [10]. Financial Performance Summary - Revenue for 2023 is projected at 2.45 billion yuan, with a year-on-year growth of 15.2%. By 2027, revenue is expected to reach 5.82 billion yuan, reflecting a growth rate of 22.7% [6]. - The net profit attributable to the parent company is forecasted to grow from 520 million yuan in 2023 to 1.85 billion yuan in 2027, with a compound annual growth rate of 33.1% [6]. - Earnings per share are expected to increase from 0.13 yuan in 2023 to 0.44 yuan in 2027 [6]. Segment Performance Summary - The analysis chromatography segment is expected to generate revenue of 610 million yuan in the first half of 2025, reflecting a year-on-year growth of 7.57% [10]. - The industrial purification segment is projected to achieve revenue of 1.20 billion yuan in the first half of 2025, with a year-on-year growth of 28.59% [10]. - The company has accumulated 87 projects in clinical phase III and commercial production stages through domestic substitution by the end of June 2025 [10].